Idenix Pharmaceuticals Provides Update On Hepatitis C Pipeline At JP Morgan Healthcare Conference

Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced an update on the company’s HCV pipeline, including promising second-generation polymerase and protease inhibitor compounds for the treatment of hepatitis C. This update will be presented on Tuesday, January 8, at 2:30 p.m.

More: continued here

Filed under: Conferences on January 8th, 2008